3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
It started on a positive note, attracting investors' attention in areas with great commercial potential, like obesity, immunology and gene therapy. However, their interest started to wane in the second half of the year amid lower-than-expected third-quarter results, guidance cuts and pipeline setbacks. While Wall Street viewed Trump's victory as an accelerant for M&A activity in the sector, the President-elect's decision to nominate vaccine skeptic Robert F. Kennedy Jr. to run the Department of Health and Human Services concerned investors in biotech stocks. These factors have negatively impacted nearly all companies in the industry. Year to date, the biotech sector has declined nearly 14%. Despite the above headwinds, we expect the biotech industry to remain a focal point for investors, driven by demand for innovative medicines. People could consider investing in biotech stocks for their high growth potential and resilience during economic downturns. The sector also benefits from
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Acknowledges the Passing of Founding Board Member David BondermanGlobeNewswire
- Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028 [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? [Yahoo! Finance]Yahoo! Finance
ALLO
Earnings
- 11/7/24 - Beat
ALLO
Sec Filings
- 12/10/24 - Form 4
- 12/9/24 - Form 4
- 12/9/24 - Form 144
- ALLO's page on the SEC website